EVOTEC SE: TRANSLATIONAL BRIDGE PARTNERSHIP beLAB2122 SELECTS ONCOLOGY PROJECT FROM GOETHE UNIVERSITY FRANKFURT
Hamburg, Germany, 4 July 2022:
- GOAL IS TO DEVELOP A BIFUNCTIONAL DEGRADER TO INTERFERE WITH THE RNA SPLICING TO DEVELOP A FIRST-IN-CLASS CANCER TREATMENT
- PROJECT ORIGINATES FROM PROF. DR IVAN ĐIKIĆ’S LAB GROUP AT THE GOETHE UNIVERSITY OF FRANKFURT
- BELAB2122 AIMS TO DEVELOP ACADEMIC PROJECTS FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY TO VALUE INFLECTION POINTS THAT ALLOW THE FORMATION OF NEW JOINTLY OWNED SPIN-OFF COMPANIES
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that a project has been selected for further development within beLAB2122, a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany to efficiently advance first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.